Vraylar is a compound being investigated for treatment of autism spectrum and adjunctive major depressive disorders.

Type of Molecule

Small Molecule


Dopanine D2 Partial Agonist, 5-HT1A Partial Agonist, 5-HT2A Antagonist

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted)
Autism Spectrum Disorder n/a
Phase 1
Adjunctive MDD n/a
Phase 3